Data de publicação: 14/12/2021 - 17:24
In a pioneering initiative, the Foundation inaugurates this Monday (13/12), COVID-19 Biobank (BC19-Fiocruz). Located in Rio de Janeiro, at Expansão campus, BC19-Fiocruz will enable the design and conduct of research, technological development and clinical trials related to COVID-19, regardless of the geographic location of human biological material and viruses. With the capacity to store up to one and a half million samples of human and...
Notícias
Data de publicação: 14/12/2021 - 16:48
A research published today by The Lancet - one of the most prestigious scientific journals focused on the medical field in the world - brought together experts to explain how the economic downturn will affect for years and will be worse in developing countries. Without a consensus for preventive action, families and communities will be disproportionately affected. In the long run, inequalities in health, physical and...
Notícias
Data de publicação: 10/12/2021 - 13:11
Fifteen years after visiting Fiocruz as a tourist, Pietro Lazzeri returned to the Foundation on Tuesday (12/07), this time as Switzerland ambassador. In office for six months, he met with Fiocruz members at the Fiocruz Global Health Center (CRIS/Fiocruz), where he proposed to expand technical and scientific cooperation. He also visited Bio-Manguinhos, where he found out that some of the machines used in the production of the COVID-19 vaccine...
Notícias
Data de publicação: 06/12/2021 - 14:57
The Oswaldo Cruz Foundation, by means of the Fio-Schisto, the Translational Research Program in Schistosomiasis, informs that researcher Otávio Pieri, of the Oswaldo Cruz Institute (IOC), was invited to become part of the World Health Organization (WHO) group on schistosomiasis and helminth diseases transmitted through the soil (geo helminth diseases). Fio-Schisto is bound to the Vice-Presidency of Biological Research and Collections....
Notícias
Data de publicação: 30/11/2021 - 12:23
Last Thursday (25 November) the Oswaldo Cruz Foundation, by means of its Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), submitted to the Brazilian Health Regulatory Agency (Anvisa) a request of post-registration alteration of its COVID-19 vaccine (recombinant), asking to include the Institute as the manufacturing unit of the Active Pharmaceutical Ingredient (API). Check out this 360º view of the production area for the...
Notícias
Data de publicação: 29/11/2021 - 10:28
Severe cases of COVID-19 are related to the ageing of the immune system and to acute immunodeficiency. It is what the new study led by the Oswaldo Cruz Institute (IOC/Fiocruz) and by the Federal University of Rio de Janeiro (UFRJ) shows, published in the academic journal Journal of Infectious Diseases.
By analyzing blood samples of patients that have been hospitalized with the disease, the researchers detected signs of hyperactivity,...
Notícias
Data de publicação: 22/11/2021 - 13:51
With two actions this week, Fiocruz became even more engaged in the fight against Hansen's, a neglected disease that had its situation aggravated during the COVID-19 pandemic. On Wednesday (11/17), the Foundation signed a Cooperation Agreement for joining the global campaign Don't Forget Hansen's Disease, with the state government and other partners, in addition to lighting the castle with purple at night as one of the actions to...
Notícias
Data de publicação: 17/11/2021 - 18:24
There are a lot of statements, and a lot of commitments as well, but there is a lack of distinction of responsibilities and of the obligation in fulfilling the goals set, which hinders the operation of the G20. That is what the participants in the latest Advanced Seminar of the Fiocruz Global Health Center (CRIS/Fiocruz) point out. The G-20 Webinar: What we should expect from the richest people in the world in global and planetary health?...
Notícias
Data de publicação: 03/11/2021 - 11:51
Last Thursday (28 October) Fiocruz signed, during a ceremony that took place at the headquarters of AstraZeneca, in Cambridge, United Kingdom, a joint declaration of commitment for the acquisition of Active Pharmaceutical Ingredient (API) with the goal of producing 60 million doses of the COVID-19 vaccine (recombinant) in order to make up the deliveries of the Foundation for 2022. The commitment signed by the institutions aims to guarantee wide...
Notícias
Data de publicação: 22/10/2021 - 09:48
Would it be possible to establish a new food model without the large producers' participation? Finding this answer is an ongoing global challenge and resounded in the seminar Food security, health and pandemics in United Nations events, organized by the Fiocruz Global Health Center (CRIS/Fiocruz). Divergent analyses and opinions revealed behind the scenes of international decisions on hunger programs and inspired empathy in provocative,...
Notícias
Data de publicação: 20/10/2021 - 10:49
A cooperation that dates back to the beginning of the last century and that has been renovated and expanded over the decades was celebrated last Thursday (October 14th), with the visit of Portugal’s assistant secretary of Health, António Lacerda Sales, to Fiocruz. Accompanied by the Secretary of State of the Portuguese Communities, Berta Nunes, and by ambassador Luís Faro Ramos, among other members of the delegation, Sales...
Notícias
Data de publicação: 18/10/2021 - 12:05
A study led by the Center for the Integration of Data and Knowledge on Health (Cidacs/Fiocruz Bahia) suggests that C-sections may be associated with a higher risk of infant mortality, with the exception of cases in which a medical indication is clear on this procedure, which is popularly known as “cesarean” in Brazil.
Photo: Courtesy
Using data collected and provided by the Ministry of Health on more than 17 million...
Notícias
Data de publicação: 16/10/2021 - 17:55
Sociologist and Fiocruz president, Nísia Trindade Lima, presented last Friday (October 8th) the conference Pandemic and Social Inequalities: Challenges for Global Health. The event was part of the Global Health Colloquium Series, a biannual series of lectures by Princeton University's Program in Global Health. Nísia thanked the university and Brazil Lab for the invitation, a hub that connects researchers and professors...
Notícias
Data de publicação: 13/10/2021 - 15:53
Fiocruz will be part, starting next week, of a Phase 3 international multicenter study with the drug Molnupiravir, manufactured by the pharmaceutical company MSD. The goal is to verify its efficiency to prevent the COVID-19 spread and transmission among people exposed to the Sars-CoV-2 virus. The study will occur simultaneously in seven centers in Brazil, two of which are under the Fiocruz responsibility: Mato Grosso do Sul and Rio de Janeiro....
Notícias
Data de publicação: 13/10/2021 - 11:13
The ambassador of Botswana to Brazil, Tebogo Montshome, visited Fiocruz last Thursday (October 7th). She decided to get to know the Foundation while visiting Rio de Janeiro to identify areas of possible cooperation between her country and the institution. Greeted by the Vice-President of Production and Innovation in Health, Marco Krieger, Montshome was particularly interested in staff training, research and production of drugs and vaccines....
Notícias
Data de publicação: 07/10/2021 - 17:11
A new study by Fiocruz on the effectiveness of vaccination in Brazil shows that the population has benefitted from the vaccination plan against the Sars-CoV-2 in the prevention of severe cases and deaths by Covid-19, although effectiveness varies between age groups. The analysis, which also included subjects vaccinated with the first dose of the Pfizer shot, was carried out between January 17 and July 19 this year, a total of six months, in...
Notícias
Data de publicação: 07/10/2021 - 14:50
In the first decades of the twentieth century, the American multinational United Fruit Company, prominent in the production and sale of tropical fruits, found a way to deal with malnutrition among its workers in Costa Rica: it imported canned and processed foods from the United States. At the same time, the solution to high infant mortality in the banana plantation zone was the introduction of an artificial food developed by Nestlé. Years...
Notícias
Data de publicação: 05/10/2021 - 17:22
Large-scale deforestation of the Amazon forest associated with climate change will increase the risk of exposure to extreme heat. Such levels of heat, which will be physiologically intolerable for the human body, will profoundly affect regions inhabited by highly vulnerable populations, according to a study published by researchers Beatriz Alves de Oliveira, of Fiocruz; Marcus Bottino and Paulo Nobre, both of the National Institute of Space...
Notícias
Data de publicação: 05/10/2021 - 16:32
The Evandro Chagas National Institute of Infectious Diseases (INI/Fiocruz) is now open for enrollment, up to November 1, into the Fourth International Course on Immunohistochemistry, Molecular Pathology and Histopathology for the Diagnosis of Infectious Diseases. Coordinated by Rodrigo Caldas Menezes, Luiz Cláudio Ferreira and Leonardo Pereira Quintella, the training is aimed at healthcare professionals, especially those that work or...
Notícias
Data de publicação: 04/10/2021 - 10:54
The COVID-19 pandemic was one of the main subjects discussed at two meetings that drew the attention of the entire world and of the region last week. While chiefs of state and of government debated the effects of the disease at the 76th General Assembly of the United Nations, at the 59th Board of Directors and 73rd Session of the Regional Committee of the World Health Organization (WHO) for the Americas, organized by the Pan-American Health...
Notícias
Data de publicação: 30/09/2021 - 14:08
By means of its Immunobiological Technology Institute (Bio-Manguinhos), last Monday (September 27th) Fiocruz ended the production of the first batches called pre-validation batches of the national Active Pharmaceutical Ingredient (API) for the COVID-19 vaccine. The ingredient will now be submitted to quality control tests at the institution to then be sent to the final processing phase of the vaccine. The first pre-validation batch, which was...
Notícias
Data de publicação: 24/09/2021 - 10:24
As part of the preparations for the new Brazilian expedition to Antarctica, Fiocruz donated 3,000 rapid tests to detect Sars-Cov-2 antigens to the Navy. The kits, produced by the Institute of Technology in Immunobiologicals (Bio-Manguinhos/Fiocruz), will be used to test the entire crew on board, on the support flights, the team at the Comandante Ferraz Antarctic Station and the researchers who will be part of the new trip - including the...
Notícias
Data de publicação: 21/09/2021 - 15:20
Researcher Jorge Bermudez, chief of the Department of Medicines Policy and Pharmaceutical Services at the Sergio Arouca National School of Public Health (ENSP/Fiocruz, in the Portuguese acronym), is now a member of the Technical Advisory Group (TAG) created to advise the World Health Organization (WHO) in scientific, technical and strategic issues related to COVID-19 Technology Access Pool (C-TAP). C-TAP is a solidarity mechanism launched...
Notícias
Data de publicação: 04/09/2021 - 12:50
The world is ageing, and it is not only in the wealthiest countries. In Brazil, this matter has an aggravating factor: while more developed nations become rich first and then age, Brazil is ageing in poverty, warns Alexandre Kalache. The president of the International Longevity Centre in Brazil, who is a doctor, was the mediator in the webinar Ageing, demographic changes and the pandemic, of the Fiocruz Global Health Center (CRIS/Fiocruz),...
Notícias
Data de publicação: 03/09/2021 - 13:06
Despite the restrictions imposed due to the pandemic, the team at the Laboratory for Clinical Research on Mycobacterioses of the Evandro Chagas National Institute of Infectology (INI/Fiocruz) considers 2021 a year of great advances. "Besides the adaptation to work in home office and the remote service implementation for patients, we have been contemplated in different national and international initiatives. This allows us to carry out new...
Notícias
O conteúdo deste portal pode ser utilizado para todos os fins não comerciais, respeitados e reservados os direitos morais dos autores.
